Enlightenment of the Fixed Reference Price System in Germany on the Medical Insurance Payment Standard for Non-exclusive Drugs in China

China Health Insurance ›› 2023, Vol. 0 ›› Issue (3) : 48-52.

China Health Insurance ›› 2023, Vol. 0 ›› Issue (3) : 48-52. DOI: 10.19546/j.issn.1674-3830.2023.3.007
International( Region) Comparison

Enlightenment of the Fixed Reference Price System in Germany on the Medical Insurance Payment Standard for Non-exclusive Drugs in China

Author information +
History +

Abstract

In June 2022, China’s National Healthcare Security Administration proposed in the Non-exclusive Drug Bidding Rules that if non-exclusive drugs were successfully included in the drug catalogue through bidding, the medical insurance payment standard for the generic name drug would be set according to the rules. Drugs with prices lower than the payment standard shall be reimbursed based on the actual price while drugs with prices higher than the payment standard, the part exceeding the standard would be paid out of pocket. This method for formulating medical insurance payment standard integrates pricing and payment, with initial practice in the 2022 adjustment of national medical insurance catalogue and far-reaching impact on China's pharmaceutical market. Internationally, Germany was the first country to establish the fixed reference price (FRP) system and may provide key learning for others. This article summarizes the design and implementation experience of the FRP system in Germany, and provides suggestions for improving relevant policies in China.

Key words

adjustment of national medical insurance catalogue / non-exclusive drug bidding / medical insurance payment standard / Germany / fixed price system

Cite this article

Download Citations
Enlightenment of the Fixed Reference Price System in Germany on the Medical Insurance Payment Standard for Non-exclusive Drugs in China[J]. China Health Insurance. 2023, 0(3): 48-52 https://doi.org/10.19546/j.issn.1674-3830.2023.3.007

References

[1] 国家医疗保障局.关于公布《2022年国家基本医疗保险、工伤保险和生育保险药品目录调整工作方案》及相关文件的公告[EB/OL].(2022-06-29)[2023-03-01].http://www.nhsa.gov.cn/art/2022/6/29/art_109_8342.html.
[2] 常峰,崔鹏磊,夏强,等.德国药品参考价格体系对构建我国医保支付标准的启示[J].中国卫生政策研究,2015,8(7):55-60.
[3] 丁锦希,白庚亮,黄泽华,等.药品医保支付价格制度框架下的支付模式实证研究[J].中国医药工业杂志, 2015, 46(06):647-652.
[4] G-BA.Festbetragsgruppenbildung[EB/OL]. (2022-07-11)[2023-03-01]. https://www.g-ba.de/themen/arzneimittel/arzneimittel-richtlinie-anlagen/festbetragsgruppenbildung/.
[5] 向国春. 从德国实践看医保药品支付标准[J]. 中国社会保障, 2018(1):80-81.
[6] SCHWABE U, PAFFRATH D, LUDWIG W D & KLAUBER, et al. Arzneiverordnungs-Report 2019[R]. Berlin, Heidelberg: Springer, 2019: 290.
[7] GKV-Spitzenverband. Geschäftsbericht2010-2016[R]. (2022-07-11)[2023-03-01]. https://www.gkv-spitzenverband.de/.
[8] Gemeinsamer Bundesausschuss. The Federal Joint Committee Decisions on ealthcareBenefits[R]. (2022-07-11)[2023-03-01]. https://www.g-ba.de/downloads/17-98-3769/2018-12--12_G-BA_Infobrosch%C3%BCre_EN_bf.pdf.
[9] GKV-Spitzenverband. Erfolgsmodell: Seit 30 Jahren sichern Arzneimittel-Festbeträge bezahlbare und hochwertige Versorgung[EB/OL]. (2022-07-11)[2023-03-01]. https://www.gkv-spitzenverband.de/gkv_spitzenverband/presse/pressemitteilungen_und_statements/pressemitteilung_864192.jsp.

Accesses

Citation

Detail

Sections
Recommended

/